{"title":"SGLT2抑制剂:有什么新进展?］","authors":"Eva Dumann, Jan Menne","doi":"10.1007/s11560-021-00511-4","DOIUrl":null,"url":null,"abstract":"<p><p>Sodium-glucose transport protein 2 inhibitors (SGLT2i, gliflozins) were originally developed for the treatment of type 2 diabetes; however, in mandatory approval studies, they demonstrated unexpected positive effects on cardiovascular endpoints and renal function. Several phase III studies published during the last year have investigated the effects of this drug class on chronic kidney disease and heart failure in diabetic and non-diabetic patients. The predominantly positive results have led to a continuing expansion of their clinical use. This article aims to provide an overview of the most recent endpoint studies on SGLT2i and show implications for practice, to present the state of knowledge on risks and side effects and to summarize current hypotheses on the mode of action of this class of drugs.</p>","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"16 4","pages":"241-255"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11560-021-00511-4","citationCount":"4","resultStr":"{\"title\":\"[SGLT2 inhibitors: What is new?]\",\"authors\":\"Eva Dumann, Jan Menne\",\"doi\":\"10.1007/s11560-021-00511-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Sodium-glucose transport protein 2 inhibitors (SGLT2i, gliflozins) were originally developed for the treatment of type 2 diabetes; however, in mandatory approval studies, they demonstrated unexpected positive effects on cardiovascular endpoints and renal function. Several phase III studies published during the last year have investigated the effects of this drug class on chronic kidney disease and heart failure in diabetic and non-diabetic patients. The predominantly positive results have led to a continuing expansion of their clinical use. This article aims to provide an overview of the most recent endpoint studies on SGLT2i and show implications for practice, to present the state of knowledge on risks and side effects and to summarize current hypotheses on the mode of action of this class of drugs.</p>\",\"PeriodicalId\":41844,\"journal\":{\"name\":\"Nephrologe\",\"volume\":\"16 4\",\"pages\":\"241-255\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s11560-021-00511-4\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nephrologe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s11560-021-00511-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/6/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrologe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11560-021-00511-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Sodium-glucose transport protein 2 inhibitors (SGLT2i, gliflozins) were originally developed for the treatment of type 2 diabetes; however, in mandatory approval studies, they demonstrated unexpected positive effects on cardiovascular endpoints and renal function. Several phase III studies published during the last year have investigated the effects of this drug class on chronic kidney disease and heart failure in diabetic and non-diabetic patients. The predominantly positive results have led to a continuing expansion of their clinical use. This article aims to provide an overview of the most recent endpoint studies on SGLT2i and show implications for practice, to present the state of knowledge on risks and side effects and to summarize current hypotheses on the mode of action of this class of drugs.
期刊介绍：
Zielsetzung der Zeitschrift
Der Nephrologe bietet aktuelle und kompakte Fortbildung für alle nephrologisch tätigen Ärzt*innen in Klinik und Praxis. Inhaltlich werden sämtliche Bereiche der angewandten Nephrologie und Hypertensiologie praxisnah abgedeckt. Das Spektrum reicht von der Prävention, diagnostischen Vorgehensweisen und Komplikationsmanagement bis hin zu modernen Therapiestrategien.
Umfassende Übersichtsarbeiten zu einem aktuellen Schwerpunktthema sind das Kernstück jeder Ausgabe. Im Mittelpunkt steht dabei gesichertes Wissen zu Diagnostik und Therapie mit hoher Relevanz für die tägliche Arbeit.
Beiträge der Rubrik "CME Zertifizierte Fortbildung" bieten gesicherte Ergebnisse wissenschaftlicher Forschung und machen ärztliche Erfahrung für die tägliche Praxis nutzbar. Nach Lektüre der Beiträge können die Leser*innen ihr erworbenes Wissen überprüfen und online CME-Punkte erwerben. Die Rubrik orientiert sich an der Weiterbildungsordnung des Fachgebiets.
Aims & Scope
Der Nephrologe offers up-to-date information for all nephrologists working in practical and clinical environments and scientists who are particularly interested in issues of nephrology.
The content covers all areas of applied nephrology and hypertensiology. The topics range from prevention to diagnostic approaches and management of complications to current therapy strategies.
Comprehensive reviews on a specific topical issue provide evidenced based information on diagnostics and therapy.
Review articles under the rubric ''Continuing Medical Education'' present verified results of scientific research and their integration into daily practice.
Review
All articles of Der Nephrologe are reviewed.
Declaration of Helsinki
All manuscripts submitted for publication presenting results from studies on probands or patients must comply with the Declaration of Helsinki.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
